Merck KGaA Highlights Mavenclad Advances In Tough Quarter
Merck KGaA's brace of new products started to garner sales in the third quarter, but the big pharma maintained its 2017 guidance at the lower end of the forecast range in the face of increasing competition to its established pharmaceutical products and to its liquid crystal materials, and currency headwinds.
You may also be interested in...
Disappointing outcome for the companies' PD-L1 inhibitor avelumab in late-stage gastric cancer may not have implications for the drug in more valuable indications, like lung cancer.
It’s an interesting challenge, commercializing in Europe the first novel pharmaceuticals to be developed and launched by Merck KGaA in a decade. The new head of its EMEA region explains his approach to the task.
Asked by Scrip to name two big changes coming pharma's way, Merck KGAA Healthcare CEO Belén Garijo identified artificial intelligence and outcome-based pacts as 'ways of the future'.